Qube Research & Technologies LTD Zentalis Pharmaceuticals, Inc. Transaction History

Qube Research & Technologies LTD

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	SELL	$9.84 - $20.13 $897,270 - $1.84 Million	-91,186 Reduced 64.49%	50,202 $760,000
Q3 2023 Nov 13, 2023	BUY	$19.63 - $28.29 $2.78 Million - $4 Million	141,388 New	141,388 $2.84 Million
Q2 2022 Aug 15, 2022	SELL	$17.91 - $52.25 $271,820 - $792,998	-15,177 Closed	0 $0
Q1 2022 May 09, 2022	BUY	$41.58 - $80.89 $264,573 - $514,703	6,363 Added 72.19%	15,177 $700,000
Q4 2021 Feb 01, 2022	SELL	$66.92 - $84.79 $41,490 - $52,569	-620 Reduced 6.57%	8,814 $741,000
Q3 2021 Nov 12, 2021	BUY	$46.83 - $73.5 $184,931 - $290,251	3,949 Added 72.0%	9,434 $629,000
Q2 2021 Aug 13, 2021	BUY	$37.41 - $62.25 $205,193 - $341,441	5,485 New	5,485 $292,000

142

67.9M

48.5K

89.6K

Ticker ZNTL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,983,600
Market Cap $171M
Description
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...

Get notified when there are updates to the investment portfolio of Qube Research & Technologies LTD, based on Form 13F filings with the SEC.

Stay updated on Qube Research & Technologies LTD with notifications on news.